Descripción general
Seleccione un tema ( ) de interés
- NEW --- COVID-19 vaccines
- UPDATED --- Management of small renal masses
- Second-line therapy in metastatic ccRCC
- Local therapy for mRCC
- First-line systemic therapy in mRCC
- Systemic therapy for HER2-positive early breast cancer
- UPDATE --- CDK4/6 inhibitors for everyone? Treatment strategies in HR+ HER2- advanced breast cancer
- UPDATED --- Radiotherapy for early breast cancer
- Systemic therapy for early stage triple-negative breast cancer
- Brain metastases in patients with HER2+ breast cancer
- NEW --- Adjuvant systemic treatment of luminal A/B early breast cancer in postmenopausal women
- NEW --- Adjuvant systemic treatment of luminal A/B early breast cancer in premenopausal women
- NEW --- Adjuvant treatment approaches for MIBC
- NEW --- Treatment of acute COVID-19
- NEW --- Acute COVID-19 in special populations
- NEW --- Long COVID
- Tratamiento inicial del dolor debido a artrosis
- Artrosis: ¿qué opciones se deben plantear después del fracaso del tratamiento?
- Tratamiento del dolor asociado a la artrosis en pacientes con enfermedades concomitantes
- Derivación y seguimiento del dolor crónico asociado a la artrosis
- High-risk non-metastatic prostate cancer
- Tailoring treatment for metastatic hormone-sensitive prostate cancer
- Finding the right ADT for the right patient
- Initial management of nocturia
- High-risk non-metastatic prostate cancer: the devil is in the details
- Tailoring treatment for metastatic hormone-sensitive prostate cancer
- Oligometastatic PCa: treating the primary and/or metastases
- Biochemical recurrence after radical prostatectomy
- CRPC: treatment in daily clinical practice
- mCRPC: novel and emerging agents
- Treatment of low and intermediate-risk PCa
- Active surveillance: yes or no?
- Adverse pathology at radical prostatectomy
- UPDATED --- Finding the right ADT for the right patient
- Management of non-neurogenic female OAB
- Treatment of high-risk PCa: the basics
- Male LUTS: keep on learning
- Challenges in high-risk NMIBC
- Low- and intermediate-risk NMIBC: surveillance or intravesical therapy?
- Follow-up surveillance regimes for low-/intermediate-risk NMIBC
- Follow-up surveillance regimes to consider for (very) high-risk NMIBC and MIBC
- Initial treatment of MIBC
- New hope for patients progressing after prior treatment for mUCa
- Immunotherapy and antibody-drug conjugates: handling AEs and special populations
- UPDATED --- First-line therapy of synchronous and metachronous metastatic UCa
- UPDATED --- Histological subtypes of (N)MIBC: managed differently compared to pure UCa?